Venture Investors
VantagePoint Venture Partners provides creative growth strategies and capital to companies transforming global markets. With more than $4.0 billion of capital under management, the Firm invests in entrepreneurial companies at all stages of development in the CleanTech, Healthcare, and Information Technology sectors. VantagePoint partners with talented entrepreneurs who are seeking to build companies that are world-scale in both size and substance. The Firm has created a network of thought leaders and strategic partners with some of the world's leading corporations to provide portfolio companies with a unique advantage to accelerate growth.
@Ventures provides venture capital and growth resources to early stage clean technology companies. Established in 1995, @Ventures has funded more than 75 companies across a broad range of technology sectors. The firm’s mission – to identify, invest in, and help build high value clean technology companies – is realized through a commitment to providing valuable expertise and financial resources, in partnership with the firm’s portfolio companies. The firm’s leadership team has many years of early-stage experience and industry contacts, enabling the firm to provide mentoring assistance and strategic and tactical advice that can help technology companies achieve their full potential.
Pinnacle Ventures is a private venture capital fund focused on providing debt and equity financing to early-stage companies across technology and healthcare. Pinnacle differentiates itself through the strength and diversity of its team, its creative and flexible financing alternatives and its unique approach to helping its portfolio companies achieve success. More information about Pinnacle Ventures can be found at http://www.pinnacleventures.com
Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses) with over $950 million under management. Burrill's technical and venture investing competence spans the entire spectrum of life sciences. The expertise of the firm's investment team, strategic partners and Advisory Boards is unparalleled in depth and breadth. In addition, Burrill is a leader in life science strategic partnering, an invaluable practice to build value in portfolio companies and to accelerate their growth and development. This combination of resources and capabilities has helped Burrill develop a unique and highly effective platform for finding and making outstanding life science investments.
The Malaysian Life Sciences Capital Fund (MLSCF) is a newly formed life sciences venture fund specializing in early stage investments in the areas of agriculture, industrial and healthcare biotechnology. The Fund is co-managed by Malaysian Technology Development Corporation Sdn Bhd (MTDC) and Burrill & Co. More information about The Malaysian Life Sciences Capital Fund (MLSCF) can be found at http://www.mlscf.com.